Lomustine
- TRADE NAMES: Belustine; Cecenu; CeeNU (Bristol-Myers Squibb); Lomeblastin; Lucostine
- INDICATIONS: Brain tumors, lymphomas, melanoma, Hodgkin's disease
- CLASS: Alkylating agent, Nitrosourea
- HALF-LIFE: 16–48 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aldesleukin, Cimetidine, Clozapine, Digoxin, Phenytoin
PREGNANCY CATEGORY: D
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric